Keytruda Combo Improves Progression, Survival in Recurrent Ovarian CancerByTim CorteseOctober 18th 2025
FDA Grants Breakthrough Status to Raludotatug Deruxtecan in Ovarian CancerBySpencer FeldmanSeptember 15th 2025